Immune-related dermatitis1


  • YERVOY™ is associated with serious skin adverse reactions that may be immune-related. Fatal toxic epidermal necrolysis has been reported in clinical trials
  • Advise patients to report skin-related changes
  • YERVOY™-induced rash and pruritus should be managed based on severity
  • Monitor patients for the most common manifestations of immune-related dermatitis, such as rash and pruritus
  • Withhold YERVOY™ in patients with severe (Grade 3) skin rash or widespread/intense pruritus regardless of aetiology
  • Permanently discontinue YERVOY™ in patients with lifethreatening skin rash (including Stevens-Johnson syndrome or toxic epidermal necrolysis) or severe widespread pruritus interfering with activities of daily living (ADLs) or requiring medical intervention
  • Systemic high-dose corticosteroids may be required



Back to Overview


1. YERVOY™ Summary of Product Characteristics.

Senast uppdaterad:  2015-07-02Ansvarig:  Anna Labecker